BRAF and melanoma: MAPK kinase inhibition with BRAF inhibitors such as vemurafenib has been shown to reduce melanoma cell proliferation and promote apoptosis, which has resulted in a clinically observable increase in progression-free survival (PFS) in melanoma patients [48].